{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T05:38:09Z","timestamp":1776922689777,"version":"3.51.2"},"reference-count":67,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009307","name":"Parkinson Society Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009307","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000226","name":"Ontario Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100025092","name":"Ministry of Health, Ontario","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100025092","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009227","name":"University of Toronto Department of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009227","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurologic Clinics"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.ncl.2024.12.013","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T08:09:43Z","timestamp":1737533383000},"page":"399-426","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Experimental Therapeutics in Parkinson\u2019s Disease"],"prefix":"10.1016","volume":"43","author":[{"given":"Priti","family":"Gros","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura Armengou","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan H.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10423","key":"10.1016\/j.ncl.2024.12.013_bib1","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0140-6736(23)01419-8","article-title":"The epidemiology of Parkinson's disease","volume":"403","author":"Ben-Shlomo","year":"2024","journal-title":"Lancet"},{"issue":"10423","key":"10.1016\/j.ncl.2024.12.013_bib2","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0140-6736(23)01429-0","article-title":"Medical, surgical, and physical treatments for Parkinson's disease","volume":"403","author":"Foltynie","year":"2024","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.ncl.2024.12.013_bib3","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/nrn.2017.62","article-title":"Non-motor features of Parkinson disease","volume":"18","author":"Schapira","year":"2017","journal-title":"Nat Rev Neurosci"},{"issue":"10423","key":"10.1016\/j.ncl.2024.12.013_bib4","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0140-6736(23)01478-2","article-title":"The pathogenesis of Parkinson's disease","volume":"403","author":"Morris","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ncl.2024.12.013_bib5","unstructured":"Parkinson\u2019s priority therapeutic clinical pipeline report 2024."},{"key":"10.1016\/j.ncl.2024.12.013_bib6","article-title":"Dopamine agonist therapy in early Parkinson's disease","volume":"2","author":"Stowe","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.ncl.2024.12.013_bib7","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/mds.29642","article-title":"A\u00a0randomized phase 3 study comparing P2B001 to its components (Low-Dose extended-release rasagiline and pramipexole) and to optimized doses of marketed extended-release pramipexole in early Parkinson's disease","volume":"39","author":"Olanow","year":"2024","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2024.12.013_bib8","unstructured":"Group LP. Luye pharma\u2019s innovative formulation LY03003 meets primary endpoints in phase III clinical trial for treating Parkinson\u2019s disease. Luye Life Sciences. (Accessed 23 July 2024)."},{"issue":"4","key":"10.1016\/j.ncl.2024.12.013_bib68","doi-asserted-by":"crossref","first-page":"476","DOI":"10.2174\/1871527322666230331121028","article-title":"Rationale and development of tavapadon, a D1\/D5-selective partial dopamine agonist for the treatment of Parkinson\u2019s disease","volume":"23","author":"Bezard","year":"2024","journal-title":"CNS Neurol Disord Drug Targets"},{"issue":"2","key":"10.1016\/j.ncl.2024.12.013_bib9","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s40120-018-0114-z","article-title":"Phase 1 Parkinson's disease studies show the dopamine D1\/D5 agonist PF-06649751 is safe and well tolerated","volume":"7","author":"Sohur","year":"2018","journal-title":"Neurol Ther"},{"key":"10.1016\/j.ncl.2024.12.013_bib10","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420911296","article-title":"PF-06649751 efficacy and safety in early Parkinson's disease: a randomized, placebo-controlled trial","volume":"13","author":"Riesenberg","year":"2020","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.ncl.2024.12.013_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2023.105907","article-title":"Randomized controlled trial of KW-6356 monotherapy in patients with early untreated Parkinson's disease","volume":"117","author":"Maeda","year":"2023","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.013_bib12","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1124\/jpet.121.000842","article-title":"First-in-Human, healthy volunteer study to investigate the safety, tolerability, and pharmacokinetics of CVN424, a novel G protein-coupled receptor 6 inverse agonist for Parkinson's disease","volume":"381","author":"Margolin","year":"2022","journal-title":"J\u00a0Pharmacol Exp Ther"},{"issue":"4","key":"10.1016\/j.ncl.2024.12.013_bib13","first-page":"1515","article-title":"The D1\/D5 dopamine partial agonist PF-06412562 in advanced-stage Parkinson's disease: a feasibility study","volume":"10","author":"Huang","year":"2020","journal-title":"J\u00a0Parkinsons Dis"},{"issue":"5","key":"10.1016\/j.ncl.2024.12.013_bib14","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/mds.29768","article-title":"Short-term cannabidiol with \u0394-9-tetrahydrocannabinol in Parkinson's disease: a randomized trial","volume":"39","author":"Liu","year":"2024","journal-title":"Mov Disord"},{"issue":"3","key":"10.1016\/j.ncl.2024.12.013_bib15","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.clnu.2018.05.018","article-title":"Clinical and metabolic response to probiotic administration in people with Parkinson's disease: a randomized, double-blind, placebo-controlled trial","volume":"38","author":"Tamtaji","year":"2019","journal-title":"Clin Nutr"},{"key":"10.1016\/j.ncl.2024.12.013_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2021.650053","article-title":"The add-on effect of lactobacillus plantarum PS128 in patients with Parkinson's disease: a pilot study","volume":"8","author":"Lu","year":"2021","journal-title":"Front Nutr"},{"issue":"12","key":"10.1016\/j.ncl.2024.12.013_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9121881","article-title":"Low-dose niacin supplementation improves motor function in US veterans with Parkinson's disease: a single-center, randomized, placebo-controlled trial","volume":"9","author":"Wakade","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.ncl.2024.12.013_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2021.667032","article-title":"Niacin enhancement for Parkinson's disease: an effectiveness trial","volume":"13","author":"Chong","year":"2021","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.ncl.2024.12.013_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2019.112226","article-title":"Efficacy of oral administration of licorice as an adjunct therapy on improving the symptoms of patients with Parkinson's disease, A randomized double blinded clinical trial","volume":"247","author":"Petramfar","year":"2020","journal-title":"J\u00a0Ethnopharmacol"},{"key":"10.1016\/j.ncl.2024.12.013_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.739194","article-title":"Pingchan granule for motor symptoms and non-motor symptoms of Parkinson's disease: a randomized, double-blind, placebo-controlled study","volume":"13","author":"Gu","year":"2022","journal-title":"Front Pharmacol"},{"issue":"12","key":"10.1016\/j.ncl.2024.12.013_bib21","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1002\/mds.28248","article-title":"Helicobacter pylori eradication in Parkinson's disease: a randomized placebo-controlled trial","volume":"35","author":"Tan","year":"2020","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2024.12.013_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.clineuro.2022.107300","article-title":"Evaluation of curcumin as add-on therapy in patients with Parkinson's disease: a pilot randomized, triple-blind, placebo-controlled trial","volume":"218","author":"Ghodsi","year":"2022","journal-title":"Clin Neurol Neurosurg"},{"issue":"5","key":"10.1016\/j.ncl.2024.12.013_bib23","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S1474-4422(24)00052-8","article-title":"Safety and efficacy of continuous subcutaneous levodopa-carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial","volume":"23","author":"Espay","year":"2024","journal-title":"Lancet Neurol"},{"issue":"12","key":"10.1016\/j.ncl.2024.12.013_bib24","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/S1474-4422(22)00400-8","article-title":"Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial","volume":"21","author":"Soileau","year":"2022","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.ncl.2024.12.013_bib25","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/mds.28926","article-title":"A\u00a0randomized trial assessing the safety, pharmacokinetics, and efficacy during morning off of AZ-009","volume":"37","author":"Thijssen","year":"2022","journal-title":"Mov Disord"},{"issue":"5","key":"10.1016\/j.ncl.2024.12.013_bib26","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13796","article-title":"Clinical trial evaluating apomorphine oromucosal solution in Parkinson's disease patients","volume":"17","author":"Thijssen","year":"2024","journal-title":"Clin Transl Sci"},{"issue":"suppl 2","key":"10.1016\/j.ncl.2024.12.013_bib27","volume":"34","author":"Shrewsbury","year":"2019","journal-title":"Mov Disord"},{"issue":"2","key":"10.1016\/j.ncl.2024.12.013_bib28","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/mds.27259","article-title":"A\u00a0randomized, double-blind, placebo-controlled trial of camicinal in Parkinson's disease","volume":"33","author":"Marrinan","year":"2018","journal-title":"Mov Disord"},{"issue":"3","key":"10.1016\/j.ncl.2024.12.013_bib29","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.792","article-title":"A\u00a0first-in-human oral dose study of mesdopetam (IRL790) to assess its safety, tolerability, and pharmacokinetics in healthy male volunteers","volume":"9","author":"Sj\u00f6berg","year":"2021","journal-title":"Pharmacol Res Perspect"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.013_bib30","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41531-018-0071-3","article-title":"Safety and tolerability of IRL790 in Parkinson\u2019s disease with levodopa-induced dyskinesia\u2014a phase 1b trial","volume":"4","author":"Svenningsson","year":"2018","journal-title":"npj Parkinson's Disease"},{"issue":"10","key":"10.1016\/j.ncl.2024.12.013_bib31","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/s40263-020-00754-0","article-title":"Non-dopaminergic treatments for motor control in Parkinson's disease: an update","volume":"34","author":"Gonzalez-Latapi","year":"2020","journal-title":"CNS Drugs"},{"issue":"Suppl 1","key":"10.1016\/j.ncl.2024.12.013_bib32","doi-asserted-by":"crossref","first-page":"S126","DOI":"10.1016\/S1353-8020(11)70039-6","article-title":"The serotonin system: a potential target for anti-dyskinetic treatments and biomarker discovery","volume":"18","author":"Rylander","year":"2012","journal-title":"Parkinsonism Relat Disord"},{"issue":"4","key":"10.1016\/j.ncl.2024.12.013_bib33","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00221-013-3621-2","article-title":"The serotonergic system in motor and non-motor manifestations of Parkinson\u2019s disease","volume":"230","author":"Huot","year":"2013","journal-title":"Exp Brain Res"},{"key":"10.1016\/j.ncl.2024.12.013_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2020.116869","article-title":"Efficacy and safety of 5-Hydroxytryptophan on levodopa-induced motor complications in Parkinson's disease: a preliminary finding","volume":"415","author":"Meloni","year":"2020","journal-title":"J\u00a0Neurol Sci"},{"issue":"5","key":"10.1016\/j.ncl.2024.12.013_bib36","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1055\/s-0043-1768668","article-title":"Doxycycline to treat levodopa-induced dyskinesias in Parkinson's disease: a preliminary study","volume":"81","author":"Santos-Lobato","year":"2023","journal-title":"Arq Neuropsiquiatr"},{"issue":"7","key":"10.1016\/j.ncl.2024.12.013_bib37","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.4103\/1673-5374.235075","article-title":"Zishenpingchan granules for the treatment of Parkinson's disease: a randomized, double-blind, placebo-controlled clinical trial","volume":"13","author":"Ye","year":"2018","journal-title":"Neural Regen Res"},{"issue":"2","key":"10.1016\/j.ncl.2024.12.013_bib38","first-page":"495","article-title":"Effects of cannabis in Parkinson's disease: a systematic review and meta-analysis","volume":"12","author":"Urbi","year":"2022","journal-title":"J\u00a0Parkinsons Dis"},{"issue":"4","key":"10.1016\/j.ncl.2024.12.013_bib39","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1089\/can.2019.0068","article-title":"Safety and tolerability of cannabidiol in Parkinson disease: an open label, dose-escalation study","volume":"5","author":"Leehey","year":"2020","journal-title":"Cannabis Cannabinoid Res"},{"key":"10.1016\/j.ncl.2024.12.013_bib40","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.parkreldis.2019.02.017","article-title":"Overview of the cholinergic contribution to gait, balance and falls in Parkinson's disease","volume":"63","author":"Morris","year":"2019","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.ncl.2024.12.013_bib41","doi-asserted-by":"crossref","first-page":"424","DOI":"10.3389\/fneur.2019.00424","article-title":"Nicotine bitartrate reduces falls and freezing of gait in Parkinson disease: a reanalysis","volume":"10","author":"Lieberman","year":"2019","journal-title":"Front Neurol"},{"issue":"12","key":"10.1016\/j.ncl.2024.12.013_bib42","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1002\/cpdd.959","article-title":"First-in-Human study to assess the safety, tolerability, and pharmacokinetics of pirepemat, a cortical enhancer, in healthy volunteers","volume":"10","author":"Rein-Hedin","year":"2021","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"4","key":"10.1016\/j.ncl.2024.12.013_bib43","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/ana.25864","article-title":"Non-motor symptoms in Parkinson's disease are reduced by nabilone","volume":"88","author":"Peball","year":"2020","journal-title":"Ann Neurol"},{"issue":"3","key":"10.1016\/j.ncl.2024.12.013_bib44","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1080\/14656566.2020.1814255","article-title":"Early-start vs delayed-start donepezil against cognitive decline in Parkinson disease: a randomized clinical trial","volume":"22","author":"Sawada","year":"2021","journal-title":"Expert Opin Pharmacother"},{"issue":"612","key":"10.1016\/j.ncl.2024.12.013_bib45","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abj2511","article-title":"In\u00a0vivo and neuropathology data support locus coeruleus integrity as indicator of Alzheimer's disease pathology and cognitive decline","volume":"13","author":"Jacobs","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ncl.2024.12.013_bib46","author":"Shapiro"},{"key":"10.1016\/j.ncl.2024.12.013_bib47","author":"Register"},{"issue":"4","key":"10.1016\/j.ncl.2024.12.013_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0214364","article-title":"Safety and preliminary efficacy of intranasal insulin for cognitive impairment in Parkinson disease and multiple system atrophy: a double-blinded placebo-controlled pilot study","volume":"14","author":"Novak","year":"2019","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.ncl.2024.12.013_bib49","doi-asserted-by":"crossref","DOI":"10.1212\/CPJ.0000000000200175","article-title":"Ulotaront, a trace amine-associated receptor 1\/serotonin 5-HT(1A) agonist, in patients with Parkinson disease psychosis: a pilot study","volume":"13","author":"Isaacson","year":"2023","journal-title":"Neurol Clin Pract"},{"issue":"11","key":"10.1016\/j.ncl.2024.12.013_bib50","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci12111466","article-title":"Vortioxetine improves depressive symptoms and cognition in Parkinson's disease patients with major depression: an open-label prospective study","volume":"12","author":"Santos Garc\u00eda","year":"2022","journal-title":"Brain Sci"},{"issue":"5","key":"10.1016\/j.ncl.2024.12.013_bib51","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/ene.14179","article-title":"Efficacy and safety of 5-hydroxytryptophan on depression and apathy in Parkinson's disease: a preliminary finding","volume":"27","author":"Meloni","year":"2020","journal-title":"Eur J Neurol"},{"issue":"4","key":"10.1016\/j.ncl.2024.12.013_bib52","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/WNF.0000000000000507","article-title":"Comparative analysis of the effects of escitalopram, pramipexole, and transcranial magnetic stimulation on depression in patients with Parkinson disease: an open-label randomized controlled trial","volume":"45","author":"Chen","year":"2022","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.ncl.2024.12.013_bib53","article-title":"Efficacy and safety of clonidine for the treatment of impulse control disorder in Parkinson's disease: a multicenter, parallel, randomised, double-blind, Phase 2b Clinical trial","author":"Laurencin","year":"2023","journal-title":"J\u00a0Neurol"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.013_bib54","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1001\/jamaneurol.2017.3171","article-title":"Sodium oxybate for excessive daytime sleepiness and sleep disturbance in Parkinson disease: a randomized clinical trial","volume":"75","author":"B\u00fcchele","year":"2018","journal-title":"JAMA Neurol"},{"issue":"2","key":"10.1016\/j.ncl.2024.12.013_bib55","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1002\/mds.28840","article-title":"THN 102 for excessive daytime sleepiness associated with Parkinson's disease: a phase 2a trial","volume":"37","author":"Corvol","year":"2022","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2024.12.013_bib56","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.parkreldis.2020.03.029","article-title":"Prolonged-release melatonin in Parkinson's disease patients with a poor sleep quality: a randomized trial","volume":"75","author":"Ahn","year":"2020","journal-title":"Parkinsonism Relat Disord"},{"issue":"10","key":"10.1016\/j.ncl.2024.12.013_bib57","doi-asserted-by":"crossref","first-page":"6141","DOI":"10.1007\/s10072-022-06188-4","article-title":"Safety and efficacy of melatonin, clonazepam, and trazodone in patients with Parkinson's disease and sleep disorders: a randomized, double-blind trial","volume":"43","author":"Hadi","year":"2022","journal-title":"Neurol Sci"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.013_bib58","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1080\/21681805.2021.1990994","article-title":"The safety and effectiveness of mirabegron in Parkinson's disease patients with overactive bladder: a randomized controlled trial","volume":"56","author":"Moussa","year":"2022","journal-title":"Scand J Urol"},{"key":"10.1016\/j.ncl.2024.12.013_bib59","unstructured":"Moussa M, Abou Chakra M, Dabboucy B, et al., Single intradetrusor injection of autologous adipose-derived stem cells in Parkinson\u2019s disease patients with overactive bladder: a pilot study, 2021. Abstract 59."},{"issue":"8","key":"10.1016\/j.ncl.2024.12.013_bib60","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1007\/s00345-019-02981-7","article-title":"Randomized, controlled trial of fesoterodine fumarate for overactive bladder in Parkinson's disease","volume":"38","author":"Yonguc","year":"2020","journal-title":"World J Urol"},{"issue":"6","key":"10.1016\/j.ncl.2024.12.013_bib61","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s10286-021-00827-0","article-title":"Safety and efficacy of ampreloxetine in symptomatic neurogenic orthostatic hypotension: a phase 2 trial","volume":"31","author":"Kaufmann","year":"2021","journal-title":"Clin Auton Res"},{"issue":"4","key":"10.1016\/j.ncl.2024.12.013_bib62","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/ene.13260","article-title":"Pyridostigmine bromide versus fludrocortisone in the treatment of orthostatic hypotension in Parkinson's disease - a randomized controlled trial","volume":"24","author":"Schreglmann","year":"2017","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.ncl.2024.12.013_bib63","unstructured":"Limwatthana C, A randomized controlled trial comparing the efficacy and safety of pyridostigmine versus midodrine for the treatment of orthostatic hypotension in Parkinson\u2019s disease patients. 2022, Abstract 740."},{"issue":"5","key":"10.1016\/j.ncl.2024.12.013_bib64","doi-asserted-by":"crossref","first-page":"e772","DOI":"10.1212\/WNL.0000000000010998","article-title":"Probiotics for constipation in Parkinson disease: a randomized placebo-controlled study","volume":"96","author":"Tan","year":"2021","journal-title":"Neurology"},{"issue":"15","key":"10.1016\/j.ncl.2024.12.013_bib65","doi-asserted-by":"crossref","first-page":"6828","DOI":"10.1039\/D3FO00728F","article-title":"Effect of Lacticaseibacillus paracasei strain Shirota supplementation on clinical responses and gut microbiome in Parkinson's disease","volume":"14","author":"Yang","year":"2023","journal-title":"Food Funct"},{"issue":"11","key":"10.1016\/j.ncl.2024.12.013_bib66","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/mds.28219","article-title":"Double-Blind, randomized, placebo-controlled trial of DA-9701 in Parkinson's disease: PASS-GI study","volume":"35","author":"Choi","year":"2020","journal-title":"Mov Disord"},{"issue":"12","key":"10.1016\/j.ncl.2024.12.013_bib67","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1002\/mds.28196","article-title":"Glycopyrrolate improves disability from sialorrhea in Parkinson's disease: a 12-week controlled trial","volume":"35","author":"Mestre","year":"2020","journal-title":"Mov Disord"}],"container-title":["Neurologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861924001087?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861924001087?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T02:19:00Z","timestamp":1762309140000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733861924001087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":67,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S0733861924001087"],"URL":"https:\/\/doi.org\/10.1016\/j.ncl.2024.12.013","relation":{},"ISSN":["0733-8619"],"issn-type":[{"value":"0733-8619","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Experimental Therapeutics in Parkinson\u2019s Disease","name":"articletitle","label":"Article Title"},{"value":"Neurologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ncl.2024.12.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}